{"id":829712,"date":"2025-03-25T16:35:55","date_gmt":"2025-03-25T20:35:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/"},"modified":"2025-03-25T16:35:55","modified_gmt":"2025-03-25T20:35:55","slug":"evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/","title":{"rendered":"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p \/>\n<ul>\n<li>\n          <b>New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting\u00a0<\/b>\n        <\/li>\n<li style=\"text-align: justify\" data-mce-style=\"text-align: justify;\">\n          <b>These data will further add to the already strong clinical data package for EVX-01<\/b>\n        <\/li>\n<li style=\"text-align: justify\" data-mce-style=\"text-align: justify;\">\n          <b>The trial remains on track for two-year clinical efficacy data readout in the second half of 2025<\/b><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, March 25, 2025 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).<\/p>\n<p align=\"justify\">Evaxion will present new biomarker and immune data obtained from the ongoing phase 2 trial. These will further add to EVX-01\u2019s already strong clinical data package.<\/p>\n<p align=\"justify\">\u201cWe are proud to be selected by the AACR\u2019s scientific committee to present new data at this very renowned and important scientific meeting. This is a testament of the high scientific value of the EVX-01 clinical program, and we are excited to get the chance to present and discuss the data with a big audience in the field of melanoma research\u201d, says Birgitte R\u00f8n\u00f8, Chief Scientific Officer of Evaxion.<\/p>\n<p align=\"justify\">The trial previously yielded strong interim one-year clinical data and remains on track for readout of two-year clinical data in the second half of 2025. Additionally, the trial has been extended with a third year, allowing for a more comprehensive assessment of the full potential of EVX-01.<\/p>\n<p align=\"justify\">\n        <b>AACR presentation details:<\/b><br \/>\n        <br \/>Abstract title:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0T-cell immunogenicity and biomarker profiling in advanced melanoma patients receiving the personalized vaccine EVX-01 in combination with pembrolizumab <br \/>Abstract#:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a04538<br \/>Poster#:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a09<br \/>Session (category):\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Immune responses to therapies including chemotherapy and radiotherapy (Clinical research)<br \/>Location:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Poster section 28<br \/>Date\/Time:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0April 29, 2025, at 9am-12pm CST\/16-19 CET \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Presenter: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Mads Lausen Nielsen, PhD, Project Manager at Evaxion<\/p>\n<p align=\"justify\">The phase 2 trial investigates EVX-01 in combination with MSD\u2019s (Merck &amp; Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA\u00ae (pembrolizumab) in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial has received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.<\/p>\n<p align=\"justify\">\n        <b>About EVX-01<\/b><br \/>\n        <br \/>EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. It is Evaxion\u2019s lead clinical asset.<\/p>\n<p align=\"justify\">EVX-01 is designed with our AI-Immunology\u2122 platform and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient&#8217;s immune system to fight off cancer by mounting a targeted response against tumors.<\/p>\n<p align=\"justify\">In clinical trials, EVX-01 has demonstrated 69% and 67% Overall Response Rates in patients with advanced melanoma. Further, significant correlations between clinical responses and AI-Immunology\u2122 predictions have been observed, underlining the predictive power of the platform.<\/p>\n<p align=\"justify\">\n        <b>Contact information<\/b>\u00a0<br \/>Evaxion Biotech A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HircMMZupTEUTQ1omSkTP5lmjT2w2DscRw65s4uAeXBcHwyYkpRhnZF9H7jg0qP3MI-cVcgoeBTj1SZyQ4zKrYr_QrZ9ciWkI8UyRpI5qUQ=\" rel=\"nofollow noopener\" target=\"_blank\" data-mce-href=\"mailto:mak@evaxion.ai\">mak@evaxion.ai<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <b>About EVAXION<\/b><br \/>\n        <br \/>Evaxion Biotech A\/S is a pioneering TechBio company based upon its AI platform, AI-Immunology\u2122. Evaxion\u2019s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology\u2122, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients\u2019 lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology\u2122 platform and vaccine pipeline, please <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5IxNB6cKSczAVSFkTTSTcL0UcGMUsPLQMdpuP6QnalB159X9Z2baWfZDd9V2p2PQ_6KBrcWG50Ore9dt32ENrezs0ycoV05g-bzCe2aBW5M=\" rel=\"nofollow noopener\" target=\"_blank\" data-mce-href=\"https:\/\/www.evaxion.ai\/\">visit our website<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statement<\/b>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geo-political and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the US Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zU8KxSKulbTp4qTkxRZoJkK1oG4jacIGmhfIOCBx6it5eoGVtzI1jVUXBPJpg87dZ6dyVAae-moplpsmx0cfV_G4utRCchr4JMQO9QHll9kWKFadiSbAwixLOaEsuYP8ci_TMv71nU8Z6dNyP8VHx36dAy-wwYOfnQlplwP_KiwKYlLoNE-igwCk8iXfuN3-8A6UN1AMru6JEVcDVxbvhGlpKBe6d9lYkd-rA61vd38=\" rel=\"nofollow noopener\" target=\"_blank\" data-mce-href=\"https:\/\/www.globenewswire.com\/Tracker?data=3eX-yULjXHj_fAO4jPRASPaehYEVHM4NmXNAs_0lw5UK0DHjLXk6aKS6LI4PyMob9UvuFpZpGQrWa4b_6WQY1A==\"><b>www.sec.gov<\/b><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MGM3MjNiMzktMzlhNC00MDZiLWFiOWMtNGZmZjcwODFlMjY4LTEyNjM2NDAtMjAyNS0wMy0yNS1lbg==\/tiny\/Evaxion-Biotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting\u00a0 These data will further add to the already strong clinical data package for EVX-01 The trial remains on track for two-year clinical efficacy data readout in the second half of 2025 COPENHAGEN, Denmark, March 25, 2025 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829712","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting\u00a0 These data will further add to the already strong clinical data package for EVX-01 The trial remains on track for two-year clinical efficacy data readout in the second half of 2025 COPENHAGEN, Denmark, March 25, 2025 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine &hellip; Continue reading &quot;Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T20:35:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting\",\"datePublished\":\"2025-03-25T20:35:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/\"},\"wordCount\":907,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/\",\"name\":\"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==\",\"datePublished\":\"2025-03-25T20:35:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting - Market Newsdesk","og_description":"New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting\u00a0 These data will further add to the already strong clinical data package for EVX-01 The trial remains on track for two-year clinical efficacy data readout in the second half of 2025 COPENHAGEN, Denmark, March 25, 2025 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine &hellip; Continue reading \"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T20:35:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting","datePublished":"2025-03-25T20:35:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/"},"wordCount":907,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/","name":"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==","datePublished":"2025-03-25T20:35:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NiM0MDIxMDE2MDkjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-to-present-new-phase-2-data-for-ai-designed-personalized-cancer-vaccine-evx-01-at-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829712"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829712\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}